Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29270787 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL17641102 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL1419600 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL5240928 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL431541 | 0.95 | HTT (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL18254066 | 0.92 | HTT (0.81) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9874334 | 0.90 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15346534 | 0.90 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9340146 | 0.90 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL176927 | 0.89 | LMNA (0.71) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4301752-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| CN-117295736-A | Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof | 剑桥实业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230373929-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2022185041-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2001058893-A2 | INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2001-08-16 | — | — | WO | disclosed |
| US-5908863-A | ANTIGROWTH AGENT FOR BONES | DOMPE' S.P.A. (IT) | 1999-06-01 | — | — | US | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| EP-0792878-A2 | Geminal carboxylic acids and esters thereof, pharmaceutical formulations containing them useful in the treatment of bone dysmetabolism | Dompé S.P.A. (IT) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| US-4742067-A | Acylalkylaminocarbonyl substituted amino and imino acid compounds | E. R. SQUIBB & SONS, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4621092-A | HYPOTENSIVE, ANALGESIC | E. R. SQUIBB & SONS, INC. (US) | 1986-11-04 | — | — | US | disclosed |
| US-4604402-A | HYPOTENSIVE AGNETS | E. R. SQUIBB & SONS, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0159156-A1 | Hydroxy substituted ureido amino and imino acids | E.R. Squibb & Sons, Inc. (US) | 1985-10-23 | — | — | EP | disclosed |
| EP-0103496-A1 | Acylalkylaminocarbonyl substituted amino and imino acid compounds | E.R. Squibb & Sons, Inc. (US) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | HTT 2658/4885TGM2 3478/4885LMNA 1058/4885 |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | HTT 4742/4885TGM2 2322/4885LMNA 2982/4885 |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | ABCB11, CEL, NDC1 | HTT 762/4885TGM2 3434/4885LMNA 438/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | HTT 2658/4885TGM2 3478/4885LMNA 1058/4885 |
| US-20230373929-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | WEE1, CYP51A1, WEE2 | HTT 4249/4885TGM2 2954/4885LMNA 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.